Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Research to Report Fiscal 2011 Second Quarter Financial Results and Host Conference Call on Thursday, May 12, 2011
Arrowhead Research to Report Fiscal 2011 Second Quarter Financial Results and Host Conference Call on Thursday, May 12, 2011 PASADENA, Calif. — May 4, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity and regenerative
View HTML
Toggle Summary Arrowhead Research to Present at the 2011 MDB Capital Group Bright Lights Conference on May 10
Arrowhead Research to Present at the 2011 MDB Capital Group Bright Lights Conference on May 10 PASADENA, Calif. — May 3, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr.
View HTML
Toggle Summary ARROWHEAD RESEARCH ANNOUNCES RNAI LEADER JOHN J. ROSSI, PH.D. TO JOIN CALANDO SCIENTIFIC ADVISORY BOARD
ARROWHEAD RESEARCH ANNOUNCES RNAI LEADER JOHN J. ROSSI, PH.D. TO JOIN CALANDO SCIENTIFIC ADVISORY BOARD PASADENA, Calif. — April 27, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced
View HTML
Toggle Summary ARROWHEAD RESEARCH INCREASES OWNERSHIP IN ABLARIS TO 64%
Ablaris Secures $2.9 Million to Enter Phase I Trial in Second Half 2011
View HTML
Toggle Summary Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16
Arrowhead Research to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on March 16 PASADENA, Calif. — March 8, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today
View HTML
Toggle Summary ARROWHEAD REPORTS FISCAL 2011 FIRST QUARTER FINANCIAL RESULTS
ARROWHEAD REPORTS FISCAL 2011 FIRST QUARTER FINANCIAL RESULTS PASADENA, Calif. – February 10, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal
View HTML
Toggle Summary Arrowhead Research to Present at the 13th Annual BIO CEO & Investor Conference
Arrowhead Research to Present at the 13th Annual BIO CEO & Investor Conference PASADENA, Calif. — February 9, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR ), a nanomedicine company, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 13th Annual BIO
View HTML
Toggle Summary Arrowhead Research to Report Fiscal 2011 First Quarter Financial Results and Host Conference Call on Thursday, February 10, 2011
Arrowhead Research to Report Fiscal 2011 First Quarter Financial Results and Host Conference Call on Thursday, February 10, 2011 PASADENA, Calif. — February 4, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a focused nanomedicine holding company, today announced that it will report its
View HTML
Toggle Summary Arrowhead Subsidiary Unidym, Inc. Acquired by Wisepower Co., Ltd. for up to $140 million earn-out plus $5 million upfront
Arrowhead Subsidiary Unidym, Inc. Acquired by Wisepower Co., Ltd. for up to $140 million earn-out plus $5 million upfront PASADENA, Calif. - January 18, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Unidym, Inc. subsidiary has been acquired by Wisepower Co., Ltd., a
View HTML
Toggle Summary Arrowhead Increases Investment in RNAi Subsidiary Calando Pharmaceuticals
Arrowhead Increases Investment in RNAi Subsidiary Calando Pharmaceuticals PASADENA, Calif. – January 18, 2011 – Arrowhead Research Corporation (NASDAQ: ARWR) (“the Company”) today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted
View HTML